Connect with us

Market

Investors Find Huge Wins With These Penny Stocks

Published

on

On Wednesday, August 12th, stocks fell over 1%. Additionally this was the second failing day in the yuan against the dollar. Investors and economists are concerned about our global growth. Dow Jones’s industrial average fell by over 250 points. This has now extended the 212-point loss from the day before – Tuesday. Nasdaq Composite has fallen 1.5% while Apple and various biotechs have continued to steeply fall. Now, what has this done to penny stocks?

Progressive Care Inc (OTCMKTS:RXMD) saw a high of $0.0125 from the opening of $0.0085. On Augusts 6th, OTCMKTS:RXMD hit a high of $0.0144. Investors are happy to see green numbers again since from August 6th to August 12th, the stock has dropped around 40%. As of 4:00 am, RXMD closed at $0.01 and is traded with a volume of 21,750,000. A recent 3 cent price target was placed on the stock by an independent analyst. This can be viewed here: http://bit.ly/RXMD_Analyst_Report

Oxis International Inc (OTCMKTS:OXIS) was at $0.0179 as of 11:35 AM on August 12th. At that same time, it was down 0.56% and the volume was at 666,242. The HOD, also at the same time, was $0.02. Just a few days before, on Monday, August 10th, OTCMKTS:OXIS saw a high $0.027. Since then, it fell 33.7% to Wednesday’s price. On August 12th, at 11:01 AM, an analyst coverage was released on the stock, keeping investors informed. An analyst report put out by Taurus Investment Research put a $0.04 price target on the stock and gave it an overall “Buy” rating. That report can be found here: http://bit.ly/OXIS_Analyst_Report

Ceres Inc (NASDAQ:CERE) had an amazing opening on Wednesday, August 12th. As of 11:45 AM, NASDAQ:CERE was up 187.58% at $2.7395. As of 11:50 AM, the stock hit a high of $4.80 which is 403% up from the previous close of $0.9526. That same morning, CERE had a press release stating that they received a patent a multi-gene trait development system for crops. This is a key milestone for the company and its future of, as they hope, more developments.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) also had a great opening on Wednesday, August 12th. As of 11:54 AM, NASDAQ:EBIO was up 81.62% at $4.25. At that same time, EBIO hit a high of $8.00 which is 241% up from the previous close of $2.34. The stock was trading at 11:55 AM with a volume of 6,087,092. EBIO also had a press release that morning. They officially had their first patients dosed with EBI-005 in a Phase 3 study. EBIO looks to be making moves, and will continue to do so in the future.

Market

Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)

Published

on

By

Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.

REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.

REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.

CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.

Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).

Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.

Continue Reading

Market

ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast

Published

on

By

ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward  to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.

ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.

CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.

MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.

The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.

Continue Reading

Market

Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)

Published

on

By

Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.

CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.

Continue Reading
Advertisement

Trending